IRadimed Q4 Revenue Rises 17% to $22.7M, Raises Guidance and Dividend
IRadimed reported Q4 2025 revenue of $22.7 million, up 17% year-over-year, following record Q3 results that led management to raise full-year guidance and declare a special cash dividend. Shares have gained 79.34% over the past 52 weeks and traded at $100.86 on February 19 with a $1.283 billion market cap.
1. Investor Letter Highlights Growth Drivers
In its Q4 2025 investor letter, Conestoga Capital Advisors highlighted IRadimed’s record third-quarter revenue and earnings, prompting management to raise full-year guidance and declare a special cash dividend, underscoring the company’s financial health and commitment to shareholder returns.
2. Quarterly Results and Market Performance
IRadimed reported Q4 2025 revenue of $22.7 million, a 17% increase compared to Q4 2024. The stock has gained 79.34% over the last 52 weeks, closing at $100.86 on February 19 with a market capitalization of $1.283 billion.
3. Niche Leadership and Hedge Fund Interest
Specializing in MRI-compatible infusion pump systems and patient monitors, IRadimed’s niche leadership and innovative product pipeline continue to draw investor attention. Hedge fund holdings increased to 14 at the end of Q3 2025, up from 13 in the previous quarter.